**CURRICULUM VITAE**

|  |  |
| --- | --- |
| **Name: Ronit Almog** | **Date: ­­­­­­­­­­­­­­­­­­21.11.2021** |
| **ID: 056171440** |

## **Personal Details**

|  |  |
| --- | --- |
| **Permanent Home Address:** | 63 Kalaniot st., Ahuzat Barak, Israel, 19323 |
| **Home Telephone Number:** | 972-4-6596203 |
| **Office Telephone Number:** | 972-4-7772380 |
| **Cellular Phone:** | 972-50-2063223 |
| **E-mail Address:** | R\_almog@rmc.gov.il; ronit2112@gmail.com |

1. **Higher Education**

|  |  |  |  |
| --- | --- | --- | --- |
| **Date of Degree** | **Degree** | **Name of Institution****and Department** | **Period of Study** |
| 1990 | M.D. with distinction | Medical School, Faculty of Medicine Technion, Israel Institute of Technology | 1977-1984 |
| 2001 | M.P.H. with distinction | School of Public Health, Hadassah Medical School, Hebrew University, Jerusalem, Israel | 1990-1991 |
| 2001 | Specialty in Public Health | Carmel Medical Center, Haifa | 1989-2001 (Alternately with military service) |

1. **Academic Ranks and Tenure in Institutes of Higher Education**

|  |  |  |
| --- | --- | --- |
| **Rank/Position** | **Name of Institution and Department** | **Dates** |
| Senior Lecturer  (part time)Adjunct Track | School of Public Health, Faculty of Health and Social Sciences, University of Haifa, Haifa, Israel | \*2010- present |
| Adjunct lecturer(1-2 courses each year)  |  Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel | 1995-2016 |
| Adjunct lecturer | Zefat Faculty of Medicine, Bar Ilan university, Israel | 2011-2014 |

1. **Offices in University Academic Administration**

|  |  |
| --- | --- |
| 2011-2016 | Head of epidemiology track, School of public health, Faculty of Social Welfare and Health Studies, University of Haifa |
| 2011-2016 | Member of teaching committee of the School of public health, University of Haifa |

1. **Scholarly Positions and Activities outside the University**

***Professional positions and activities***

|  |  |
| --- | --- |
| ***Current positions*** |  |
|  |  |
| \*2014- present | Director of Epidemiology unit and Chife data scientist, Rambam health care campus  |
| \*2012- present | Founding director of Hospital Integrated Bioresource for Research (Biobank), Rambam health care campus |
| \*2009-present | Consultant to medical professional societies of physicians, for planning, designing and implementing of clinical and epidemiological national registries (Israel Medical Association and unpaid helper since 2011)  |
| \*2016-present | Member of Rambam Health Care Campus bourd of directors |
| ***Past Professional positions*** |  |
| 1999-2007 | Deputy director, Clalit Health Services (CHS) National Israeli Cancer Control Center |
|  | Deputy Director, Department of Community Medicine and Epidemiology, Carmel Medical Center and the Bruce Rappaport Faculty of Medicine, Technion, Haifa.  |
| 2000-2006 | Leading the service and quality control activities of the Clalit Health Services (CHS) national program for early detection of colorectal cancer. |
| 2001-2002 | Head of the research team and of the medical check up teams for the "National Investigation Committee of the Effects of Military Activities in the Kishon River and the Region’s Water on the Health of IDF Soldiers Activated There" (Shamgar committee). |
| ***Past Professional positions (continue)*** |  |
| 2000-2006 | Head of a team for development, management and quality control of Clalit Health Services (CHS) national registry of chronic diseases. |
| 2008 | Advisor for Clal Health Insurance Company on strategic decisions according to expected long term health needs and health services use. |
| 2008-2010 | Scientific manager of the medical committee for health technologies basket update of the Israeli Medical Association (Israel Medical Association)  |
| 2008- 2011 | Head of research unit, department of medical policy, Israeli Medical Association (Israel Medical Association).  |
| 2009 | Member of professional committee of the Ministry of Health for evaluation of cancer research needs in Israel.  |
| 2010 | Member of a professional committee of the Ministry of Health for early detection of colorectal cancer in Israel.  |
| 2009-2011 | Head of a professional committee for recommending to the Ministry of Health on guidelines for activities after screening testing for CMV in pregnancy  |
| 2009-2014 | Head of IDF professional committee on periodical health examination for standing army soldiers |
| 2014 | Member of Ministry of Health professional committee for updating the list of reported diseases by law |
| 2013- 2017 | Head of examination committee of the Israeli Association of Public Health Physicians (Israel Medical Association) |
| 2018 | Member of the quality control committee of the Israeli organ transplantation center of the ministry of health, for heart and lung transplantations in Israel |
| \*2019-2020 | Member of Higher & Genetic Helsinki Committee, Ministry of Health, Israel |
| ***Professional service at the IDF (Israeli Defense Force)*** |  |
| 1985- 1989 | Military physician, the Israel Defense Force (IDF). |
| 1991-1993 | Head of Epidemiology Department, IDF Public Health Branch (Major). I was in charge of the surveillance, research, and control of infectious diseases among soldiers including policy decision making regarding vaccination programs. |
| 1997-1999 | Head of the Military Central District Health Services Center for Primary & Secondary Medical Services, IDF (Major) |

***Professional Training***

|  |  |
| --- | --- |
| 1984 | Internship at Haemek Hospital, Afula, Israel |
| 1989-1991 | Residency training in Public Health in the department of Family and Community Medicine, Carmel Medical Center, Haifa, Israel |
| 1993- 1997 | Continued (following a service in a military position) residency in Public Health, Department of Community Medicine and Epidemiology, Carmel Medical Center, Haifa. |
| 1996-1997 | Clinical rotations in Internal Medicine and Neurology Departments, Carmel Medical Center.  |
| 2005 | NCI summer curriculum in cancer prevention and control and Molecular Cancer Prevention Course, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA |
|  |  |
| ***Research activities (major )*** |  |
| 1990-19962016- present | Infectious disease epidemiology and control methods |
| 1993- present | Cancer etiology- risk factors and gene-environment interactions-Planning and conducting of a national, population based, case-control study on Hepatocellular carcinoma (HCC) in Israel. |
|  | Co-investigator in population based international research activities in molecular epidemiology of cancer, including:* MECC (Molecular Epidemiology of Colorectal Cancer) study - NCI funded research on molecular and environmental epidemiology of colorectal cancer in Israel
* BCA- molecular and environmental epidemiology of breast cancer in Israel
 |
| 2000-present | Cancer screening- methods, decision making, planning, evaluation and quality control of screening methods and national screening programs  |
| 2012-present | Biologic therapy targeting in inflammatory bowel disease and rheumatologic diseases |
| 2012-present | Innovative tools in clinical big data analysis for real world effectiveness studies, predictive modeling and decision support tools. Leading the research based on secondary data analysis at Rambam, and previously at Clalit Health Services.  |

***Membership in scientific review committee***

|  |  |
| --- | --- |
| 2007- 2016 | Member, Ministry of Health - Head Scientist Review Committee on Epidemiology, Public Health |
|  2008- present | Reviewer of scientific research grant proposals to the Preventive Action and Research on the safety and health at work at Department of Supervision of Labor Ministry of Industry  |
| 2009- present | Reviewer of grant proposals to the Israel Science Foundation (ISF) |
| 2012- present | Reviewer of grant proposals to the Israel Cancer Association (ICA) |
| 2016-present | Head of scientific board for clinical reasearch grants, Rambam health care |

***Membership in professional organizations***

|  |  |
| --- | --- |
| 1985-present | Israel Medical Association (IMA) |
| 1989-2002 | Israel Association of Epidemiology |
| 1995-2007 | American Association of Preventive Oncology (ASPO) |
| 2005-presnt | Israel Association of Public Health Physicians |
| 2010-2013 | American Association of Cancer research (AACR) |
| 2011-present | European Public Health Association (EUPHA) |
| 2012-present | European, Middle eastern & African Society for Biopreservation and Biobanking (ESBB) |
| 2013-present | International Society for Biological and Environmental Repositories (ISBER) |

1. **Participation in Scholarly Conferences**

a. **Active Participation**

***International Conferences***

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Date** | **Name of Conference** | **Place of Conference**  | **Subject of Lecture/Discussion** | **Role** |
| 1993 | Regional European Meeting of the International Epidemiological Association | Jerusalem, Israel, February  | An increased incidence of food-borne outbreaks of streptococcal pharyngitis in the I.D.F | Presenter |
| 1994 | Sixth I.D.F. Medical Corps - USAMRDC (U.S. Army medical R&D Command. Infectious diseases of vaccines of Military Importance | Israel | Clusters of Meningococcal disease and emergence of rifampicin resistance in the I.D.F. | Presenter |
| 2000 | American Society of Preventive Oncology (ASPO) | Washington DC, USA | Hepatitis B and C Infection and Hepatocellular Carcinoma in Israel, National case-control study | Presenter |
| 2000 | European Association of Cancer Research (EACR) – XVI | Halkidiki, Greece | Hepatitis B and C Infection and Hepatocellular Carcinoma in Israel, National case-control study | Presenter |
| 2000 | International Society for Hereditary Gastrointestinal Tumors- 12th ICG-HNPCC meeting  | Tiberias, Israel | 1. Preliminary correlates of microsatellite instability in a population based study | Presenter |
| 2. Hereditary Nonpolyposis colorectal cancer among Sephardi Jews | Presenter |
| 2002 | American Society of Preventive Oncology (ASPO) | Washington DC, USA | 1. Prognosis of BRCA1 and BRCA2 mutation carriers with breast cancer | Presenter |
| 2. Colorectal phenotype of carriers of the APC I1307K mutations | Presenter |
| 2002 | Union International Cancer Control (UICC) | Oslo, Norway | 1. Colorectal phenotype of carriers of the APCI1307K mutations | Presenter |
| 2. Characteristics of breast cancer in carriers of BRCA1 and BRCA2 in an Israeli cohort study | Presenter |
| 3. Colorectal cancer in Jews and Arabs in Israel | Presenter |
| 2004 | CHS (Clalit Health Services) International Cancer Prevention Conference | Dead Sea | 1. Prognosis of BRCA1 and BRCA2 Mutation Carriers With Breast Cancer | Presenter |
| 2. Colorectal Phenotype of Carriers of the APCI1307K Mutations | Head of panel |
| 3. Women’s Satisfaction From Mammography Units | Head of panel |
| 4. Carotenoid Isomers and Colorectal Cancer | Poster |
| 5. Correlates of micro satellite instability in a population based study of Colorectal Cancer in Israel | Presenter |
| 2005 | American Society of Preventive Oncology (ASPO) | San Francisco | Physical Activity protects against Colorectal Cancer | Presenter |
| 2007 | Setting an ethical agenda for health promotion | Ghent, Belgium | Individuals' rights regarding colorectal cancerscreening: choosing their preferred technology, ornot wishing to decide | Presenter |
| 2012 | European, Middle eastern & African Society for Biopreservation and Biobanking (ESBB)  | Granada, Spain | Status and future directions for biobank network in Israel: The Israel Joint Collaborative Bioresource for Research (IJCBR) | Poster |
| 2017 | Global Biobank Week –yearly conference of the ESBB (European, middle eastern, african, Society for Biopreservation and Biobanking) | Stockholm, Sweden | Hospital-based biobanking in Israel: which potential donors refuse and why? | Poster  |

***Local Conferences***

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Date** | **Name of Conference** | **Place of Conference**  | **Subject of Lecture/Discussion** | **Role** |
| 1990 | Israeli Epidemiological Association | Jerusalem, Israel | Considerations in health services planning in an atmosphere of uncertainty: the case of coronary artery bypass surgery in Israel | Presenter |
| 1992 | Israeli Epidemiological Association | Jerusalem, Israel | Recorded outbreaks of meningococcal disease in the Israel defense force | Presenter |
| 2004 | Annual conference of the Israeli Association for Medical Informatics | Tel Aviv | Administrative Databases as an information resource for chronic diseases database – strengths and weaknesses | Presenter |
| 2007 | The Sixth Annual Health Policy Conference, Israel | Tel Aviv, Israel | The public prefers fecal occult blood test over colonoscopy as a method for colorectal cancer early detection | Presenter |
| 2007 | Mid-year conference of the Israeli Association of Gastroenterology and Liver Diseases | Herzelia, Israel | What are the public preferences for the early detection of colorectal cancer: Colonoscopy or Feacal Occult Blood Test? | Presenter |
| 2007 | Israeli Sociology Society 38th Annual meeting | Haifa, Israel | Individuals' rights regarding colorectal cancer (CRC) screening: choosing their preferred technology and the privilege to give up self-decision. | Presenter |
| 2008 | Annual meeting of the Israel Association of Public Health Physicians  | Kfar Maccabiah, Ramat-Gan, Israel  | Faecal occult blood test performance indicators in warfarin treated patients | Presenter |
| 2009 | Annual conference of the Israeli Association for Medical Informatics | Tel Aviv | Database for the management of scientific evaluation and decision making process of health technologies proposed for the Israeli health basket- needs and solutions | Presenter |
| 2009 | Ethical dilemmas in public health | “Ma’ale Hachamisha” | Ethical dilemmas in decision making about screening programs (Head of discussion group and round table) | Head of panel |
| 2010 | Evidence based practice in health and social welfare sciences- from theory to “real-life” | University of Haifa | Evidence based practice in the process of health technologies basket update –from theory to practice | Presenter |

***Articles presented by other partners***

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Date** | **Name of Conference** | **Place of Conference**  | **Subject of Lecture/Discussion** | **Presenters** |
| 1999 | American Society of Clinical Oncology (ASCO) |  | APC I1307k allele and the risk of hepatocellular carcinoma | Gruber S., **Almog R**., Low M., Rennert G. |
| 2001 | SER | Toronto, Canada | 1. A retrospective cohort study of prognosis of BRCA1 and BRCA2 mutation carriers: first results and methodological considerations | Bisland-Becktell S., Rennert G, **Almog R**, Zhang S, Narod SA |
| 2. Prevalence of Microsatellite Instability in a Population-Based Study of Colorectal Cancer in Israel  | Gruber SB, Greenson JK, Tomsho LA, Bonner JD, Kim E, Rennert HS, **Almog R**, Low M, Rennert G.  |
| 2003 | National Cancer Institute (NCI) Cancer Family Registries (CFRs) Meeting | Hawaii | Characteristics of breast cancer in carriers of BRCA1 and BRCA2 in an Israeli cohort study | Rennert G, Bisland-Becktell S, **Almog R**, Bar-Joseph N, Zhang S, Rennert HS, Narod S |
| 2005 | Cancer in Developing Countries | Cairo | Reproductive risk factors for breast and colorectal cancers in the Arab population in Israel | Shakour SK, **Almog R**, Gruber SB, Low M, Pinchev M, Reisfeld D, Rennert HS, Tamir A, Rennert G.  |
| 2005 | American Association of Cancer Research (AACR) prevention |  Baltimore  | 1. CYP19 Polymorphisms are Associated with Familial Breast Cancer Risk in Ashkenazi Jews | Raskin L, Lejbkowicz F, Barnett-Griness O, Reisfeld D, Dishon S, **Almog R**, Rennert G.  |
| 2. Hypothyroidism and the Risk of Colorectal Cancer | Rennert G, **Almog R**, Bonner JD, Rennert HS, Pinchev M, Low M, Gruber SB. |
| 2006 | Society of Behavioral Medicine’s 27th Annual Meeting | San Francisco | 1. First decade of the Israeli National program for early detection of breast cancer | Hagoel L., Rennert G., **Almog R.** |
| 2. Women’s overall satisfaction with mammography units of the National Israeli Breast Cancer Detection Program. What makes the difference? | Hagoel L., Rennert G., **Almog** R. |
|  2007 | 10th International Conference, Primary Therapy of Early Breast Cancer | St.Gallen, Switzerland | Breast cancer in Arab and Jewish women in Israel: Differences in clinical and pathological characteristics | Sikorsky N., **Almog R**., Tamir A., Pinchev M., Leitzin L., M. Shtainer. |
|  2007 |  American Society of Clinical Oncology (ASCO) | Chicago, USA | BRCA1 breast cancer risk is modified by CYP19 polymorphisms in Ashkenazi Jews. | Raskin L, Lejbkowicz F, Barnett-Griness O, Reisfeld D, Dishon S, **Almog R**, Rennert G. |
| 2013 | 8th congress of ECCO (European Crohn and Colitis Organization) | Vienna, Austria | Evaluating Adalimumab drug and antibody levels as predictors of clinical and laboratory response in Crohn's disease patients  | Y. Mazor, U. Koplov, D. Ben Hur, **R. Almog**, M. Waterman, S. Ben-Horin, Y. Chowers |
| 2013 | 2013 congress of the Israeli Association of gastroenterological and liver diseases | Eilat  | Evaluating Adalimumab drug and antibody levels as predictors of clinical and laboratory response in Crohn's disease patients  | Y. Mazor, U. Koplov, D. Ben Hur, **R. Almog**, M. Waterman, S. Ben-Horin, Y. Chowers |
| 2014 | Yearly conference of the Israeli neurological association | Israel | Cognitive function is associated with intestinal disease activity as well as with biomarkers of nutrition and inflammation in patients with Crohn`s disease  | Golan D, Gross B, Miller A, Klil Drori S, **Almog R,** Lavi I, Honigman S, Shiller M, Segol O |
| 2015 | Digestive Disease Week (DDW) 2015 | USA | Thiopurines reduce infliximab anti-drug antibody formation unrelated to initial thiopurine response in Crohn's disease patients treated by thiopurine & infliximab co-therapy   | H. Bar-Yoseph, M. Waterman, **R. Almog**, T. Billiet, S. Vermeire, B. Ungar, H. Yanai, I. Dotan, S. Ben-Horin, Y. Chowers |
| 2015 | European Crohn's and Colitis Organisation (ECCO) 10th congress | Spain | Thiopurines reduce infliximab anti-drug antibody formation regardless of their initial therapeutic effect in Crohn's disease patients | H. Bar-Yoseph, M. Waterman, **R. Almog**, T. Billiet, S. Vermeire, B. Ungar, H. Yanai, I. Dotan, S. Ben-Horin, Y. Chowers |
| 2015 | 2015 Canadian Surgery Forum | Canada | Robotic versus laparoscopic versus open gastrectomy forgastric adenocarcinoma. | E. Kakiashvili, E. Brauner, O. BenYshai, **R. Almog**, A. Beny, Y. Kluger.  |
| 2017 | 16th World Congress In Fetal Medicine | Slovenia | Prevalence of GBS Bacteria among Jewish Parturients in Northern Israel - a Comparison between Observant and Secular WomenPrevalence of GBS Bacteria among Jewish Parturients in Northern Israel - a Comparison between Observant and Secular Women | Adi Sharabi-Nov, **Ronit Almog,** Inbar Ben Shachar, David Peleg |
| 2017 | ESPID (European (Society for Pediateric Infectious Diseases |  | Viral Respiratory Infection among Immunosuppressed Children - Epidemiology and Characteristics | Timianker G, **Almog R**, Kassis I, Ben Barak A, Shachor-Meyouhas Y |
| 2018 | ESPID (European Society for Paediatric Infectious Diseases) | Malmo, Sweden | The pneumococcal vaccine effect on the epidemiology of community acquired bacteremia (CAB) among children in Israel during the years 2004-2016 | D. Geller, **R. Almog**, Y. Geffen, I. Kassis |

1. **Invited lectures**

|  |  |  |  |
| --- | --- | --- | --- |
| **Presentation/Comments** | **Name of Forum** | **Place of Conference** | **Date** |
| The role of hepatitis B, C and alcohol in hepatocellular carcinoma (HCC) in Israel following the Russian immigration. | GI malignancies can be prevented and treated: from the bench to the bedside. | Dead Sea, Israel. International meeting | 2001 |
| Epidemiology of chronic wounds.  | First Israeli conference on epidemiology and treatment of chronic wounds | Technion, Bruce Rappaport Faculty of Medicine, Haifa, | 2001 |
| What a researcher should know before using administrative health services databases as a resource of data for research  | Research group of the North district of Family physicians association | Technion, Haifa | 2006 |
| Standard national screening policy – is it a violation of individual’s rights? | Rethinking Public Health Law and Ethics Conference | Bar-Ilan University school of Law |  2008 |
| Debate on CRC screening policy for average risk population in Israel. Do we have to change the current policy of the ministry of health about early detection of CRC ?  | Annual meeting of the Israel Association of Public Health Physicians | Kfar-Maccabia, Ramat-Gan | 2008  |
| Lecture and discussion moderator of round table with invited guest Prof. David Lieberman (USA) on “ Colonoscopy data base in Israel”  | Colorectal cancer can be prevented. Israel Gastroenterology association (IGA)and Israel Cancer Association (ICA) meeting  | “Bet Mati”, ICA, Givatayim |  2009 |
| Ethical dilemmas in decision making about screening programs (Head of discussion group and round table) | Ethical dilemmas in public health | “Ma’ale Hachamisha” |  2009 |
| Point Counterpoint debate on mammography: National mammography screening program should be continued.  | 26th conference of family medicine | Avenue convention center, Kfar Truman  |  2009 |
| National Israeli Registry of Biological Drugs in Rheumatologic Diseases | Annual meeting of the Israeli Society of Rheumatology  | Kfar Bloom | 2010 |
| Point Counterpoint debate on the preferred method for early detection of Colorectal Cancer (CRC) in light of sigmoidoscopy trial results | North district Family physicians continue education | Technion, Haifa | 2011 |
| Evidence based basis for the new ministry of health guidelines for CMV screening and following activities during pregnancy | Gynecologists working at the ministry of health family health stations | Ramat Efal | 2011 |
| Genetic polymorphism and gene-environment interactions – Epidemiologic aspects in cancer prevention and in personalized medicine  | Educational workshop for oncologists on cancer biology in the era of personalized medicine | Tel-Aviv | 2012 |
| Criteria for ethical screening programs – What physicians need to know before recommending helical CT examination for lung cancer early detection? | Haifa and northern Israel multidisciplinary association of lung cancer treatment and research | Haifa | 2012 |
| Screening for cancer early detection | 3rd National Israeli conference of community oncology  | Nazareth | 2014 |
| Lung cancer epidemiology in Israel | CME Course (Israeli CME Credits):Integrating 20 Years Of Experience In Lung Cancer Screening Into Everyday Practice:An International 2-Day Intensive CourseFor Practicing Clinicians | Tel Aviv | 2015 |
| Debate- Early detection of colorectal cancer, colonoscopy or fecal occult blood test? | 1st Israeli conference of debates in community treatment of gastric and hepatic diseases | Herzliya | 2015 |

1. **Research Grants**
2. **Grants Awarded**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Year** | **Funded by** | **Topic** | **Co-Researchers** | **Role in Research** |
| 1993 | Israeli Ministry of Health, Chief Scientist NIS 56,000 | Hepatitis B and C as risk factors for hepatocellular carcinoma in Israel | G. Rennert (Co-PI) | **Co-PI** |
| 1996 | Israeli Ministry of Health, Chief Scientist NIS 56,000 | Cobalamin Deficiency and Associated Neurologic Impairment among young Israeli Adults | S. Honigman (CI) | **PI** |
| 2002 | National Institute for Health Policy Research NIS 702,000 (3 years) | Quality Control in a National Program for the Early Detection of Breast Cancer | G. Rennert (Co-PI) | **Co-PI** |
| 2012 | National Institute for Health Policy Research NIS 150,000 | Assessment of disease activity in rheumatic patients by rheumatology nurses- feasibility study of validity and practicability  | O. Elkayam (Co-PI) | **Co-PI** |
| 2016 | Israel ministry of environmental protection- Chief Scientist2,000,000 NIS | Environmental Exposures and Fetal Growth: The Haifa Pregnancy Cohort Study | Hagai Levine (PI) | **\*CI** |
| 2018 | Israel Innovation Authority2,500,000 NIS | Development and validation of automated natural language and machine learning processing of textual pathology reports of malignancies to structured tables | Yaniv Zohar (CI)Irit Ben-Aharon (CI) Anat Reiner Benaim (CI) | **\*PI** |

1. **Scholarships, Awards and Prizes**

Hebrew university, Medicine Faculty Award on the name of J. Schmerler for distinction in MPH thesis.

1. **Teaching**
2. **Courses Taught in Recent Years**

***Institution:*** *University of Haifa, School of Public Health*

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Year** | **Title** |  **Type of Course**  | **Degree****B.A./M.A./M.Sc/Ph.D.** | **Numbers of Students** |
|  \*2009-2018 | Making sense of data. Lecturer (and Course leader of 5 lecturers)  | Mandatory Course  | M.P.H | 100-130 |
|  \*2007, 2021 | Research methods. Lecturer | Mandatory Course | M.P.H | 30 |
| 2019-2020 | Final projects guidence | Mandatory course | M.P.H | 20 |
| \*2005 - present | Molecular Epidemiology and Chemoprevention. Lecturer | Elective course | M.P.H | 10-20 |
| \*2005 - present | Early Detection of Diseases. Lecturer | Elective course | M.P.H | 15-30 |

***Institution:*** *Technion, Faculty of Medicine, Haifa, Israel*

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Year** | **Title** |  **Type of Course**  | **Degree****B.A./M.A./M.Sc/Ph.D.** | **Number of Students** |
| 2010-2016 | Basic Epidemiology course. Lecturer  | Introduction mandatory course | M.D | 110 |
| 2014 | Basic Epidemiology (English course). Lecturer  | Introduction mandatory course | M.D | 30 |
| 2004 -2010 | Basic Epidemiology course. Co-lecturer | Introduction mandatory course | M.D | 70-100 |
| 2013 | Public health. Co-lecturer | Elective course | M.D | 40 |
|  2008 | Research methods and biostatistics. (English course)Co-lecturer | Introduction mandatory course | M.D (TeAMS) | 40 |
| 1992-2007 | Elective course in research methods. Co-lecturer | Elective course | M.D/Ph.D/M.Sc | 13-20 |

***\*Institution:*** *Bar Ilan university**, Faculty of Medicine, Zefat, Israel*

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Year** | **Title** |  **Type of Course**  | **Degree****B.A./M.A./M.Sc/Ph.D.** | **Number of Students** |
| 2011-2014 | Basic Epidemiology course. Lecturer  | Mandatory course | M.D | 70 |

1. **Supervision of Graduate Students**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Name of Student** | **Title of Thesis** | **Degree** | **Date of Completion /****in Progress** | **Students' Achievements** |
| \*Marcelo Low | Association between personal and environmental antibiotic exposure and acquired uropathogenic resistant bacteria in the community - A multilevel hierarchical model | PhD | 2018 | Publication # 33, 34, 35 in published articles list |
| \*Wesal Shihade  | Epidemiology, Comorbidities, and Prediction of Survival in Patients with Bullous Pemphigoid in Northern Israel | MPH | 2018 | 86 |
| \*Dan Geler | Community-acquired bacteremia among children hospitalized at RHCC 2004-2016 and the impact of pneumococcal conjugate vaccine-13 on the incidence and causative pathogen | MD (Technion) | 2018 | 91 |
| \*Gal Timianker Meron | Viral respiratory infection among children treated in hemato-oncology department – Clinical and epidemiological characteristics | MD (Technion) | 2017 | 97 |
| \*Adi Nov Sharabi | Determinants associated with GBS (Group B Streptococci) prevalence among Jewish pregnant women at delivery | MPH | 2017 | 95 |
| \*Idit Lavi | Antidepressant use and the risk of acute coronary event and overall mortality- nested case control study  | MPH | 2017 | 95Publication # 31 in published articles list |
| Daud Firas | Risk factors of carbapenem-resistant Klebsiella pneumoniae carriage | MPH | 2015 | 92 |
| Daniel Golan | Cognitive functioning of Crohn's disease patients and the association with dietary status | MPH | 2015 | 97Publication # 28 in published articles list |
| Rola Hamood | Adherence to Evidence-Based Therapy after Acute Myocardial Infarction and Its  Impact on All-Cause Mortality | MPH | 2013 | 97 Publication # 27 & #29 in published articles list |
| Shlomit Riskin | Quality of treatment in diabetic women before and during pregnancy by socio-demographic determinants  | MPH | 2013 | 95Publication # 24 & #26 in published articles list |
|  Gili Ezra | Public preferences and barriers regarding early detection of colorectal cancer | Master thesis. Hebrew university Jerusalem  | 2007  | 88Publication #17 in published articles list |

**Physicians in Basic Sciences Training**(Part of the requirements for specialty)

|  |  |  |  |
| --- | --- | --- | --- |
| **Name of Student** | **Title of Thesis**(presented for review to the scientific committee of the medical association) | **Date of Completion /** **in Progress** | **Students' Achievements**  |
| Dr. Geva Barzilai, Otolaryngology Department, Carmel Medical Center | Clinical characteristics and survival in a series of larynx cancer patients.  | 2005  |  |
|  Dr. Alex Yosipovitz, Geriatric Department, Carmel Medical Center | Fear of death among hospitalized elderly patients compared to their children perceptions thereof.  | 2006  | #16 in published articles list |
| \*Dr. Ronen Shai | Door to Balloon Time in Primary Percutaneous coronary Intervention in ST Elevation Myocardial Infarction- Every Minute Counts. | 2020 |  |
|  Dr. Natalia Sikorski, Oncology Institute, Lin Clinic and Carmel Medical Center | Clinical and pathological characteristics of breast cancer in Jewish and Arab women | 2006  |  |

# PUBLICATIONS

**First author is the main contributor, last author is usually the group head, the rest appear according to their relative contribution (unless otherwise specified).**

**A. M.D Thesis**

**Title:** The risk of postoperative haemorrhage in tonsillectomy as an outpatient procedure in children.

**Language:** Hebrew

**Supervisor:** Rosen G, M.D

**Institute:** Faculty of Medicine, Technion, Israel Insitute of Technology, Haifa

**Publication**: Otorhinolaryngol. 1997 Jul 18 41(1):29-36 (#5 in published articles list)

**M.P.H. Thesis (with distinction)**

**Title:** The effect of the Iraki missile attack in the Gulf war on the incidence of myocardial infarction and sudden cardiac death in the Haifa region.

**Language:** Hebrew

**Supervisor:** Prof. Kark JD

**Pages**: 107

**Institute:** School of Public Health, Hadassa Medical School, Hebrew University, Jerusalem

**B.** **Scientific Books (Refereed)**

None

**C. Monographs**

None

**D. Articles in Refereed Journals**

**Published**

1. **Almog R**, Epstein L. (1992) "Considerations in Health Services Planning in an Atmosphere of Uncertainty: The case of coronary artery bypass surgery in Israel.
Israel Journal of Medical Sciences; 28:52-60. ( IF= 0.510, Q0)
2. Lerman Y., Shohat T., Asheknazi S., **Almog R**., Heering SL, Shemer J.(1993) "Efficacy of Different doses of Immune Serum Globulin in the prevention of Hepatitis A: A three-year prospective study". Clinical Infectious Diseases**;** 17:411-4.
(IF= 6.186, Q10, Rank 6/265 in Infectious Diseases, V)
3. **Almog R**., Block C., Gdalevich M., Lev B., Wiener M., Ashkenazi S. (1994) "First Recorded Outbreaks of Meningococcal Disease in the Israel Defense Force - Three clusters due to Serogroup C and the Emergence of resistance to rifampicin". Infection; 22:69-71. ( IF= 2.368, Q17, Rank 75/265 in Infectious Diseases, V)
4. Bar-Shany S, Gilon E, **Almog R**, Ashkenazi S. (1994) "Transient anti-hepatitis C antibodies after influenza vaccination" [letter]. Infection; Oct 22(5): 367.
(IF= 2.368, Q0, Rank 75/265 in Infectious Diseases, V)
5. Rakover Y, **Almog R**, Rosen G.( 1997) "The risk of postoperative haemorrhage in tonsillectomy as an outpatient procedure in children". International Journal of Pediatric Otorhinolaryngology. 41(1):29-36. ( IF= 0.846, Q33 , Rank 33/101 in Otorhinolaryngology, V)
6. Low M, **Almog R**, Green MS, Ashkenazi S, Bercovier H, Katzenelson E, Ashkenazi I, Shmer J, Cohen D. (1998) "Immune status against diphtheria among immigrants from the former USSR who arrived in Israel during 1990-1991". Infection 26(2) 104-8.
(IF= 2.368, Q4, Rank 75/265 in Infectious Diseases, V)
7. **Almog R,** Low M, Cohen D, Robin G, Ashkenazi S, Bercovier H, Gdalevich M, Samuels Y, Ashkenazi I, Shemer J, Eldad A, Green MS ( 1999) " Prevalence of anti-hepatitis A antibodies, hepatitis B viral markers, and anti-hepatitis C antibodies among immigrants from the former USSR who arrived in Israel during 1990-1991"***.*** Infection 27(3): 212-7. ( IF= 2.368, Q17, Rank 75/265 in Infectious Diseases, V)
8. Hagoel L, Dishon S, **Almog R**, Silman Z, Rennert G. (2000) "Proband family adherence to familial-genetic counseling" Psycho-Oncology 9: 522-527.
(IF= 2.772, Q14, Rank 62/320 in Oncology, V)
9. Gruber SB., Ellis NA., Rennert G., Offit K., et al. Scott KK., **Almog R**., Kolachana P., Bonner JD., Kirchoff T., Tomsho LP., Nafa K., Pierce H., Low M., Satagopan J., Rennert H., Huang H., Greenson JK., Groden J., Rappaport B., Shia J., Johnson S., Gregersen PK., Harris CC., Boyd J.(2002). "BLM heterozygosity and the risk of Colorectal Cancer" Science297 (#5589): 2013. ( IF= 30.028, Q108, Rank 1/132 in History and Philosophy of Science, V)
10. Greenson JK, Bonner JD, Ben-Yzhak O, Cohen HI, Miselevich I, Resnick MB, Trougouboff P, Tomsho LD, Kim E, Low M, **Almog R**, Rennert G, Gruber SB. (2003)
"Phenotype of microsatellite unstable colorectal carcinomas: Well- differentiated and focally mucinous tumors and the absence of dirty necrosis correlate with microsatellite instability". American Journal of Surgical Pathology. 27(5):563-70.
(IF= 4.144,Q135, Rank 3/375 in Surgery, V)
11. Niell BL., Rennert G., Bonner JD., **Almog R**., Tomsho L., Gruber SB. (2004) "BRCA1 and BRCA2 founder mutations and the risk of colorectal cancer". Journal of the National Cancer Institute; 96:15-21. ( IF= 15.271, 46, Rank 6/320 in Oncology, V)
12. Miller A., M. Korem, **R. Almog**, Y. Galboiz . (2005) Vitamin B12, Demyelination, Remyelination and Repair in Multiple Sclerosis. Journal of the Neurological Sciences; 233:93-97. ( IF= 2.412, Q43, Rank 49/144 in Neurology, V)
13. Poynter JN, Gruber SB, Higgins PDR, **Almog R**, Bonner JD, Rennert HS, Low M, Greenson JK, Rennert G. (2005) "Statins and the Risk of Incident Colorectal Cancer". New England Journal of Medicine; 352:2184-92. (IF= 51.296, Q484, Rank 2/1775 in Medicine (miscellaneous), V)
14. Rennert G, **Almog R**, Tomsho LP, Low M, Pinchev M, Chaiter Y, Bonner JD, Rennert HS, Greenson JK, Gruber SB (2005). "Colorectal polyps in carriers of the APC I1307K polymorphism". Diseases Colon Rectum 48:2317-21. (IF= 2.442, Q11, Rank 7/131 in Gastroenterology, V)
15. **Almog** **R.,** Hagoel L., Tamir A., Barnett O., Rennert G. (2008) "Quality Control in a National Program for the Early Detection of Breast Cancer Women’s Satisfaction With the Mammography Process". Women's Health Issues18(2):110-117. (IF= 1.843, Q11, Rank 22/229 in Health (social science), V)
16. Sinoff G., Iosipovici A., **Almog R.,** Barnett-Greens O. (2008) “Children of the elderly are inapt in assessing death anxiety in their own parents”. International Journal of Geriatric Psychiatry23(11): 1207-1208. IF= 2.197, Q1, Rank 12/108 in Geriatrics and Gerontology, V (mistake in order of names, I had to be the last instead of the statistician Barnett-Greens. I was the scientific guide of Dr. Yosipovici in planning, conducting and analysis the study and his official basic science training)
17. **Almog R.,** Gili Ezra G., Lavi I., Rennert G., Hagoel L. (2008) "The Public Prefers Fecal Occult Blood Test over Colonoscopy For Colorectal Cancer Screening". European Journal of Cancer Prevention 17(5):430-437. (IF= 1.993, Q16, Rank 38/83 in Epidemiology, V)
18. Raskin L, Lejbkowicz F , Barnet-Griness O, Dishon S, **Almog R,** Rennert G. (2009) “BRCA1 Breast Cancer Risk Is Modified by CYP19 Polymorphisms in Ashkenazi Jews”. Cancer Epidemiology, Biomarkers and Prevention 18(5):1617-23
(IF= 4.770, Q6, Rank 13/83 in Epidemiology, V)
19. Chaiter Y, Gruber SB, Ben-Amotz A, **Almog R**, Rennert HS, Fischler R, Rozen G, Rennert G. (2009) “Smoking attenuates the negative association between carotenoids consumption and colorectal cancer risk”. Cancer Causes and Control. 20(8): 1327-1338
(IF= 3.690, Q13, Rank 63/320 in Oncology, V)
20. Neter E, **Almog R**, Ore L, Rennert G, Hagoel L. (2009) “Women as the target population: the first decade of the israeli national program for early detection of breast cancer”. Cognition, brain and behavior. 8(2):195-205 (Rank 117/118 in Experimental and Cognitive Psychology)
21. Kershenbaum A, Lavi I, Rennert G, **Almog R**. (2010) “Faecal occult blood test performance indicators in warfarin treated patients” Diseases of the colon and rectum.
53(2): 224–229. (IF= 2.615, Q7, Rank 7/131 in Gastroenterology, V)
22. Koifman E,Karban A, Mazor Y, Chermesh I, Waterman M, **Almog R**, Ben-Horin S, Eliakim R, Krivoy N, Efrati E, Chowers Y (2013) "Thiopurine Effectiveness in Patients with Crohn's Disease: A Study of Genetic and Clinical Predictive Factors" Inflamm Bowel Dis 19(8):1639-44 (IF= 4.464, Q2, Rank 8/131 in Gastroenterology, V)
23. Cohen Y, **Almog R**, Onn A, Itzhaki-Alfia A, Meir K (2013) "Establishing and sustaining a biorepository network in Israel: challenges and progress." Biopreserv Biobank Dec;11(6):331-8. ( IF= 1.340, Q3, Rank 104/207 in Biochemistry, Genetics and Molecular Biology, V)
24. Riskin-Mashiah S, Auslander R, **Almog R**. "The quality of periconception medical care in women with diabetes needs improvement." Diabetes Care 2014 Mar; 37(3):678-85. (IF= 8.570, Q0, Rank 3/214 in Endocrinology, Diabetes and Metabolosm, 7/131 in Gastroenterology)
25. Mazor Y = [[1]](#footnote-1)**Almog R,** Kopylov U, Ben Hur D, Blatt A, Dahan A, Waterman M, Ben-Horin S, Chowers Y. "Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn's disease." Aliment Pharmacol Ther 2014 Sep; 40(6):620-8. ( IF=5.727, Q9, Rank 6/248 in Pharmacology, V)
26. Riskin-Mashiah S, **Almog R**. "Missed opportunities for appropriate postpartum care in women with pregestational diabetes." J Matern Fetal Neonatal Med 2015 Aug 17:1-5. (IF= 1.367, Q0, Rank 58/173 in Obstetrics and Gynecology, V)
27. Hamood H, Hamood R, Green MS, **Almog R**. "Effect of adherence to evidence-based therapy after acute myocardial infarction on all-cause mortality." Pharmacoepidemiol Drug Saf. 2015 Oct; 24(10):1093-104. (IF= 2.939, Q1, Rank 22/83 in Epidemiology, V)
28. Golan D, Gross B, Miller A, Klil-Drori S, Lavi I, Shiller M, Honigman S, [[2]](#footnote-2)**Almog R** = Segol O. " Cognitive Function of Patients with Crohn's Disease is Associated with Intestinal Disease Activity". Inflamm Bowel Dis 2016 Feb;22(2):364-71
(IF= 4.464, Rank 8/131 in Gastroenterology, V)
29. Hamood H, Hamood R, Green MS, **Almog R**. "Determinants of adherence to evidence-based therapy after acute myocardial infarction." Eur J Prev Cardiol 2016 Jun;23(9):975-85 (IF= 3.319, Rank 27/83 in Epidemiology, V)
30. Bar-Yoseph, H., Waterman, M., **Almog, R.**, Billiet, T., Vermeire, S., Ungar, B., Chowers, Y. (2017). Prevention of Antidrug Antibody Formation to Infliximab in Crohn’s Patients With Prior Failure of Thiopurines. Clinical Gastroenterology and Hepatology. 2017 Jan;15(1):69-75.
31. **Almog R**, Carasso S, Lavi I, Amir O. The risk for a first acute coronary syndrome in patients treated with different types of antidepressants: A population based nested case-control study. Int J Cardiol. 2018 Sep 15;267:28-34.
32. Golan R, Kloog I, **Almog R,** et al. Environmental exposures and fetal growth: The Haifa pregnancy cohort study David Stieb, Cecile Boot, Michelle Turner, Osmar Zaiane. BMC Public Health. 2018 Jan 12;18(1):132.
33. \*Low M, **Almog R**, Balicer RD, et al. Infectious disease burden and antibiotic prescribing in primary care in Israel. Ann Clin Microbiol Antimicrob. 2018 Jun 9;17(1):26.
34. \*Low M, , Neuberger A., Hooton TM., Green MS., Raz R., Balicer RD, **Almog R**. The association between urinary community-acquired fluoroquinolone-resistant Escherichia coli and neighborhood antibiotic consumption: a population-based case-control study.
Lancet Infect Dis. 2019 Mar 4. pii: S1473-3099(18)30676-5.
35. \*Gottesman BS, Low M, **Almog R**, Chowers M. Quinolone Consumption by Mothers Increases Their Children's Risk of Acquiring Quinolone-Resistant Bacteriuria. Clin Infect Dis. 2020 Jul 27;71(3):532-538. doi: 10.1093/cid/ciz858. PMID: 31504346.
36. \*Goshen-Lago T., Szwarcwort-Cohen M., Benguigui M., **Almog R.,** Turgeman I., Zaltzman N., Halberthal M., Shaked Y., Ben-Aharon I. The Potential Role of Immune Alteration in the Cancer-COVID19 Equation-A Prospective Longitudinal Study. Cancers (Basel). 2020 Aug 26;12(9):2421.
37. \*Eviatar T, Zisman D, Gendelman O, Reitblat T, Balbir-Gurman A, Mashiach T, **Almog R**, Elkayam O. Secukinumab real world drug retention compared to TNF-alpha inhibitors in psoriatic arthritis. Clin Exp Rheumatol. 2021 Jan 7. Epub ahead of print. PMID: 33427613.
38. \*Reiner Benaim A, **Almog R**, Gorelik Y, Hochberg I, Nassar L, Mashiach T, Khamaisi M, Lurie Y, Azzam ZS, Khoury J, Kurnik D, Beyar R. Analyzing Medical Research Results Based on Synthetic Data and Their Relation to Real Data Results: Systematic Comparison From Five Observational Studies. JMIR Med Inform. 2020 Feb 20;8(2):e16492. doi: 10.2196/16492. PMID: 32130148; PMCID: PMC7059086.
39. \*Gottesman BS., Low M, **Almog R**., Chowers M. Quinolone Consumption by Mothers Increase Their Children's Risk to Acquire Quinolone- Resistant Bacteriuria. Clin Infect Dis. 2020 Jul 27;71(3):532-538.
40. \*Shouval A, Lidar M, Reitblat T, Zisman D, Balbir-Gurman A, Mashiach T, **Almog R**, Elkayam O. Real-world effectiveness of tofacitinib in patients with rheumatoid arthritis: a prospective observational study. Clin Exp Rheumatol. 2021 Jan 10. Epub ahead of print. PMID: 33427626.
41. \*Kakiashvili E., Bez M., Abu Shakra I., Ganam S., Bickel A., Merei F., Drobot A., Bogouslavski G., Kassis W., Khatib K., Badran M., Kluger Y., **Almog R.** Robotic inguinal hernia repair: Is it a new era in the management of inguinal hernia? Asian J Surg. 2021 Jan;44(1):93-98.
42. \*Reiner Benaim A, Sobel JA, **Almog R,** Lugassy S, Ben Shabbat T, Johnson A, Eytan D, Behar JA. Comparing COVID-19 and Influenza Presentation and Trajectory. Front Med (Lausanne). 2021 May 14;8:656405. doi: 10.3389/fmed.2021.656405. PMID: 34055833; PMCID: PMC8160103.
43. \*Dabaja-Younis H, Geller D, Geffen Y, [[3]](#footnote-3)**Almog R**, Kassis I. The impact of pneumococcal conjugate vaccine-13 on the incidence of pediatric community-acquired bacteremia. Eur J Clin Microbiol Infect Dis. 2021 Jul;40(7):1433-1439. doi: 10.1007/s10096-021-04167-9. Epub 2021 Feb 3. PMID: 33537906.
44. \*Khateb A, Deshpande A, Feng Y, Finlay D, Lee JS, Lazar I, Fabre B, Li Y, Fujita Y, Zhang T, Yin J, Pass I, Livneh I, Jeremias I, Burian C, Mason JR, **Almog R**, Horesh N, Ofran Y, Brown K, Vuori K, Jackson M, Ruppin E, Deshpande AJ, Ronai ZA. The ubiquitin ligase RNF5 determines acute myeloid leukemia growth and susceptibility to histone deacetylase inhibitors. Nat Commun. 2021 Sep 13;12(1):5397. doi: 10.1038/s41467-021-25664-7. PMID: 34518534.
45. \*Waldhorn I, Holland R, Goshen-Lago T, Shirman Y, Szwarcwort-Cohen M, Reiner-Benaim A, Shachor-Meyouhas Y, Hussein K, Fahoum L, Peer A, **Almog R**, Shaked Y, Halberthal M, Ben-Aharon I. Six Month Efficacy and Toxicity Profile of BNT162b2 Vaccine in Cancer Patients with Solid Tumors. Cancer Discov. 2021 Sep 2:candisc.1072.2021. doi: 10.1158/2159-8290.CD-21-1072.
46. \*Turgeman I, Goshen-Lago T, Waldhorn I, Karov K, Groisman L, Reiner Benaim A, **Almog R**, Halberthal M, Ben-Aharon I. Psychosocial perspectives among cancer patients during the coronavirus disease 2019 (COVID-19) crisis: An observational longitudinal study. Cancer Rep (Hoboken). 2021 Aug 18:e1506. doi: 10.1002/cnr2.1506. Epub ahead of print. PMID: 34405968; PMCID: PMC8420321.
47. \*Elalouf O, Lidar M, Reitblat T, Zisman D, Balbir-Gurman A, Hakakian O, Mashiach T, **Almog R**, Elkayam O. High Body Mass Index is Associated with Shorter Retention of Tumor Necrosis Factor-Alpha Blocker Treatment in Rheumatoid Arthritis. Biologics. 2021 Jul 20;15:279-287. doi: 10.2147/BTT.S290169. PMID: 34321864; PMCID: PMC8312506.
48. \*Timianker Meron G, **Almog R**, Kassis I, Ben-Barak A, Shachor- Meyouhas Y. Viral respiratory infection among children treated in hemato-oncology department – Clinical and epidemiological characteristics. Pediatric Hematology Oncology Journal 2021 June; 6(2): 91-96. doi:10.1016/j.phoj.2021.01.004.
49. \*Goshen-Lago T, Waldhorn I, Holland R, Szwarcwort-Cohen M, Reiner-Benaim A, Shachor-Meyouhas Y, Hussein K, Fahoum L, Baruch M, Peer A, Reiter Y, Almog R, Halberthal M, Ben-Aharon I. Serologic Status and Toxic Effects of the SARS-CoV-2 BNT162b2 Vaccine in Patients Undergoing Treatment for Cancer. JAMA Oncol. 2021 Oct 1;7(10):1507-1513. doi: 10.1001/jamaoncol.2021.2675. PMID: 34236381; PMCID: PMC8267843.

**E. Articles or Chapters in Scientific Books**

 **(which are not Conference Proceedings)**

**Published**

1. Miller A., Gross B., Rawashdi H., **Almog R**., Honigman S., Barak M., Gruener N. Changes in Serum and Cerebrospinal Fluid Superoxide Dismutase and Neuron-Specific Enolase Following Acute Cerebral Ischaemia. (2 pages)
 Advances In Critical Care Testing: The IFCC-AVL Award 1996. Eds. List, W. F., Muller MM., McQueen MJ. , 1997, Springer-Verlag Berlin and Heidelberg GmbH & Co. KG, 180 pages, ISBN: 3540625909

**F. Articles in Conference Proceedings**

**Published**

1. Block CS., Davidson Y., **Almog R**., Gdalevich M., Ashkenazi S.
“Factors associated with meningococcal carriage in a defined military population. Pathology & Immunobiology of Neisseriaceae”. Proceedings of the VIII International Pathogenic Neisseria Conference. Conde-Glez C.J., Morse S., Rice P., Sparling F., and Calderon E. (eds). Instituto Nacional de Salud Pública, Cuernavaca, Morelos, Mexico, 1994, 169-175
2. Rennert G, Bisland –Becteil S, Almog R, Zhang S, Rennert HS, Narod S. (2002) "Prognosis of BRCA1 and BRCA2 mutation carriers with breast cancer" Cancer Epidemiology Biomarkers & Prevention, Vol 11, No 2:221
3. Raskin L, Lejbkowicz F , Barnet-Griness O, Reisfeld D, Dishon S, **Almog R,** Rennert G. (2007) “BRCA1 breast cancer risk is modified by CYP19 polymorphisms in Ashkenazi Jews” Journal of Clinical Oncology, ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 25, No 18S (June 20 Supplement), 2007: 10511
4. Kakiashvili, E. Brauner, O. Ben Yshai, **R. Almog**, A. Beny, Y. Kluger. Robotic versus laparoscopic versus open gastrectomy for gastric adenocarcinoma. J can chir, 2015: Vol. 58, (4 Suppl 2),

**G. Entries in Encyclopedias**

None

**H. Other Scientific Publications**

1. **Almog R,** Rennert G. (1995) Cost Effectiveness of Adult Pneumococcal Vaccination in Israel. Clalit Health Services publication.
2. Rennert G., **Almog R**., Miron E., Peterburg Y. (1997). Updating the Health Services Basket of the National Health Law. 101 pages
 National Institute for Health Policy Research publication
3. **Almog R**, Shakur S., Berlen M., Rennert G.,. (2003). Health profile and health services utilization among Clalit Health Services members by residency settlement. Clalit Health Services publication.
4. **Almog R.,** Ore L., Keinan-Boker L., Hagoel L.(2008)Early detection of Colorectal Cancer (CRC) in an average risk asymptomatic population. 15 pages
Position paper of the Israeli Association of Public Health Physicians, Israel Medical Association (IMA)

 **I. Other Publications**

1. Ministry of health guidelines on CMV screening of pregnant women (Hozer 25/11).
**Almog R** (Head of committee) and the committee for recommending to the Ministry of Health on guidelines for activities after screening testing for CMV in pregnancy

**J. Other Works Connected with my Scholarly Field**None

**K. Submitted Publications**

1. Gottesman B, Low M, Balicer R, Netzer D, [[4]](#footnote-4)**Almog R**, Chowers M. Community antibiotic prescriptions declined during COVID-19 era: A population-based cohort study.
2. Marcusohn E, Reiner Benaim A, Ronen S, Kerner A, Beyar R, **Almog** **R**. Door to Balloon Time in Primary Percutaneous coronary Intervention in ST Elevation Myocardial Infarction- Every Minute Counts.
3. Shachor-Meyouhas Y, Hussein K, Dabja-Younis H, Szwarcwort-Cohen M, Almog R, Weissman A, Mekel M, Hyams G, Horowitz N, Gepstein V, Netzer I, Cohen Saban H, Petersiel N, Tarabeia J, Halberthal M. Immunogenicity Trends One and Three Months after Second BNT162B2 Vaccination Among Healthcare Workers in Israel (CMI J accepted)

 **Summary of my Activities**

My past experience was characterized in combining public health practice with research in a wide range of fields:

* **Infectious diseases monitoring, control and research** (Israeli Defense Force (- immunization status of populations, outbreak investigation, transmission methods, and the effectiveness of different control measures. Covid-19 natural history and vaccination research.
* **Cancer control and molecular etiologic research** -gene-environment interactions, and population based molecular epidemiology research in cancer (PI and Co-PI in large population based case-control studies of HCC, CRC, BC).
* **Screening for the early detection of diseases** -evaluation of the scientific/medical/social/ethical criteria for recommending a screening program to national health decision makers (Ministry of Health, Clalit health services, Israeli Defence Force); screening program planning, implementation, and evaluation of process quality and goal achievement (breast and colorectal national screening programs). Teaching courses specifically representing this universe of knowledge.
* **National patient registries -** planning, designing, linkage and interfacing with other electronic health records, data collection and quality assurance of disease and other health related patients’ databases (Clalit Health Services, National Chronic Diseases registry, National Adverse drug events reporting registry, National Biologic Drugs registry in rheumatology, IBD registry)
* **Health technology assessment and health policy development-** analysis and interpretation of data from administrative and clinical databases and the integration with scientific data for health policy decision making, evidence based reviews, needs assessment and cost benefit models of new drugs, instruments, treatment methods, surgical and others.
* **Quality assurance of Israeli National public health interventions and services -** as deputy director of the two national programs for the early detection of breast and colorectal cancers
* **Investigation of diseases clusters-** leading the research/medical examinations projects for the "National investigation committee for the effects of military activities in the Kishon river on the health of IDF soldiers activated there" (Shamgar committee), and the research on the Iraqi missile attack (in the Gulf war, 1991) effects on the incidence of myocardial infarction and sudden cardiac death in the Haifa region.
* **Use of innovative tools for big data** **analysis**- leading the research based on secondary data analysis at Rambam, I am responsible for developing of new and innovative methods for validating and analyzing the data stored at health records as well as from monitors and other digital sources in order to promote real world effectiveness studies, predictive modeling and decision support tools.
1. Equal contribution with Mazor Y as first [↑](#footnote-ref-1)
2. Equal contribution with Segol O as last [↑](#footnote-ref-2)
3. Equal contribution with Kassis I as last [↑](#footnote-ref-3)
4. Equal contribution last [↑](#footnote-ref-4)